Abstract
- •
Venous thrombosis is common in patients with severe COVID-19 pneumonia.
- •
Many of these thromboses may be immunothromboses due to local inflammation, rather than thromboembolic disease.
- •
Anticoagulated patients with COVID-19 pneumonia have a risk of major bleeding.
Keywords:
COVID-19; Critical care; Pulmonary embolism; SARS-CoV-2; Venous thromboembolism.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anticoagulants / therapeutic use
-
Betacoronavirus / isolation & purification
-
COVID-19
-
Coronavirus Infections / complications*
-
Coronavirus Infections / epidemiology
-
Coronavirus Infections / therapy
-
Critical Care
-
Dalteparin / therapeutic use
-
Extracorporeal Membrane Oxygenation
-
Female
-
Humans
-
Male
-
Middle Aged
-
Pandemics
-
Pneumonia, Viral / complications*
-
Pneumonia, Viral / epidemiology
-
Pneumonia, Viral / therapy
-
Retrospective Studies
-
SARS-CoV-2
-
Tertiary Healthcare
-
Thromboembolism / diagnostic imaging
-
Thromboembolism / drug therapy
-
Thromboembolism / etiology*
-
Thromboembolism / therapy
-
Ultrasonography, Doppler
-
United Kingdom / epidemiology
-
Young Adult
Substances
-
Anticoagulants
-
Dalteparin